Key oncology conferences like ASCO, ASH, and ESMO drive investment-informing clinical research, with recent ESMO 2024 data highlighting significant advancements in immunotherapy. Merck's ...

Space electronic warfare — the art and science of protecting and denying satellite signals — has become a key part of how ...

Before the annual congress of the European Society for Medical Oncology began in Barcelona, clinicians held a press ...

BARCELONA, Spain — Ten years ago, a new type of cancer treatment reached the market. It worked by rousing the body’s own immune cells to attack tumors. Within months, regulators had approved ...

The European Society for Medical Oncology (ESMO) is calling on all actors of the oncology community to commit to improving the well-being of the cancer workforce and join in 11 actions outlined in a ...

Jazz’s Global Head of R&D Robert Iannone, M.D., told Fierce Biotech ahead of ESMO that today’s updated results “reaffirm zanidatamab’s potential as a foundational treatment for patients ...

Lantheus may have been hoping that “statistically significant” phase 3 data for its radioligand therapy would make a splash at ESMO, but not everyone is impressed. The biotech used the ...

But it’s an issue that scientists discussing the trials raised throughout ESMO. Merck partnered with Eisai back in 2018 to expand the latter company’s Lenvima into new cancer indications ...

In an email, the company pointed out that the majority of patients in LITESPARK-005 received Welireg as their third or fourth-line treatment (87.4%) after being treated with PD-1/L1 inhibitor and ...

Taking to the stage for the 2024 European Society for Medical Oncology (ESMO) Meeting in Barcelona, Spain, Exact Sciences said the study sought to simulate the screening population to predict the ...

At the European Society of Medical Oncology (ESMO) Congress 2024, recent results from the single-arm open-label DESTINYBreast-012 trial evaluating Daiichi Sankyo’s Enhertu (trastuzumab ...

Researchers explored HER2 testing discordance, biomarkers of response, patient-reported outcomes, and the risk of lung-related disease.